share_log

CinCor Pharma, Anavex Life Sciences And Some Other Big Stocks Moving Lower On Monday

Benzinga Real-time News ·  Nov 29, 2022 00:31

U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Monday. Here are some big stocks recording losses in today's session.

  • CinCor Pharma, Inc. (NASDAQ:CINC) shares tumbled 46.9% to $14.08 after the company announced topline data for the Phase 2 HALO trial evaluating Baxdrostat in uncontrolled hypertension. HALO did not achieve statistical significance on its primary endpoint.
  • Anavex Life Sciences Corp. (NASDAQ:AVXL) dipped 17.3% to $9.83 after the company reported worse-than-expected Q4 EPS results.
  • Community Health Systems, Inc. (NYSE:CYH) declined 13% to $3.1150.
  • The Hain Celestial Group, Inc. (NASDAQ:HAIN) dropped 12.6% to $18.05. Hain Celestial Group appointed Wendy P. Davidson as President and Chief Executive Officer, effective January 1, 2023.
  • Satixfy Communications Ltd. (NYSE:SATX) declined 11.7% to $20.21.
  • Fluence Energy, Inc. (NASDAQ:FLNC) dropped 11.5% to $16.42.
  • Energy Vault Holdings, Inc. (NYSE:NRGV) declined 11% to $4.4077.
  • NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) shares fell 10.6% to $9.00.
  • Prime Medicine, Inc. (NASDAQ:PRME) dipped 10.2% to $18.60.
  • Scilex Holding Company (NASDAQ:SCLX) fell 10.2% to $4.33.
  • ReneSola Ltd (NYSE:SOL) dropped 9.6% to $4.29. Himanshu H. Shah was recently appointed as Chairman of the Board of ReneSola Power.
  • Check-Cap Ltd. (NASDAQ:CHEK) fell 9.1% to $3.49.
  • Polestar Automotive Holding UK PLC (NASDAQ:PSNY) dropped 8.8% to $7.29.
  • Opendoor Technologies Inc. (NASDAQ:OPEN) dipped 8.5% to $1.8950.
  • Diana Shipping Inc. (NYSE:DSX) fell 7.5% to $3.6550.
  • ProKidney Corp. (NASDAQ:PROK) dropped 7.1% to $8.62. ProKidney recently posted a Q3 loss of $0.13 per share.
  • DraftKings Inc. (NASDAQ:DKNG) fell 3.7% to $14.59. JP Morgan downgraded DraftKings from Neutral to Underweight and announced $12 price target.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment